Core Viewpoint - The report from CICC maintains the EPS forecast for Chaoyujian Ophthalmology (02219) at 0.28 CNY and 0.30 CNY for 2025 and 2026, respectively, with a target price of 3.90 HKD, indicating a 30.0% upside potential from the latest closing price [1] Group 1: Financial Performance - In 1H25, the company reported revenue of 698 million CNY, a year-on-year decrease of 4.9%, and a net profit attributable to shareholders of 114 million CNY, down 16.7%, primarily due to the impact of high-value consumables procurement and price adjustments in certain refractive surgeries [1] - The overall performance was in line with CICC's expectations [1] Group 2: Operational Metrics - The number of outpatient visits decreased by 8.6% to 522,000, while inpatient visits fell by 2.7% to 35,000, and optical center visits dropped by 5.8% to 49,000 in 1H25 [2] - Despite the decline in visit volumes, the average spending per outpatient increased by 4.3% to 797 CNY, and the average spending per optical center customer rose by 12.7% to 978 CNY [2] - The revenue from consumer ophthalmology services was 359 million CNY, down 4.6%, accounting for 51.5% of total revenue, while basic ophthalmology services generated 337 million CNY, down 5.6%, making up 48.3% of total revenue [2] Group 3: Competitive Strategies - The company has adopted new refractive techniques in its four hospitals, providing differentiated pricing options, with a significant increase in the adoption rate and market acceptance [3] - The company plans to enhance the promotion of these new techniques in the second half of the year, expecting a substantial increase in the average price of refractive surgeries [3] Group 4: Profitability and Cost Management - The gross margin for 1H25 was 42.6%, a decrease of 3.1 percentage points year-on-year, while the net profit margin was 16.3%, down 2.3 percentage points, mainly due to price reductions in the all-laser refractive surgery and the impact of high-value consumables procurement [4] - The company has shown improved cost control, with combined management and sales expense ratios decreasing by 1.5 percentage points to 21.6% [4]

消息面上，朝聚眼科发布2025年中期业绩，该集团取得收益6.98亿元，同比减少4.91%；母公司拥有人 应占溢利1.14亿元，同比减少16.72%。不派中期息。公告称，收益减少主要由于以基础眼科服务为主的 门诊就诊次数及住院就诊次数略有下降；及为应对日益激烈的市场竞争及中国的集采报量(VBP)国家政 策，自2024年下半年起在集团内部进行定价调整所致。 智通财经APP获悉，朝聚眼科(02219)跌12%，截至发稿，跌12%，报2.64港元，成交额740.38万港元。 ...

Core Viewpoint - The company reported a decrease in revenue and profit for the six months ending June 30, 2025, primarily due to a decline in outpatient and inpatient visits, as well as pricing adjustments in response to market competition and national policies [1] Financial Performance - The company achieved revenue of 698 million, a year-on-year decrease of 4.91% [1] - Profit attributable to the parent company was 114 million, reflecting a year-on-year decrease of 16.72% [1] - Basic earnings per share were 0.16 [1] Operational Challenges - The decline in revenue was attributed to a slight decrease in outpatient and inpatient visit numbers, which are primarily focused on basic ophthalmic services [1] - The company plans to implement internal pricing adjustments starting in the second half of 2024 to address increasing market competition and the impact of the national volume-based procurement (VBP) policy [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219.HK), reported a decline in revenue and profit for the six months ending June 30, 2025, primarily due to decreased patient visits and pricing adjustments in response to market competition and national policies [1] Financial Performance - Revenue decreased by 4.9% to RMB 698 million [1] - Net profit fell by 17.1% to RMB 110 million [1] - Profit margin declined from 18.2% in the same period of 2024 to 15.9% for the six months ending June 30, 2025 [1] - Basic earnings per share decreased by 17.2% from RMB 0.20 in 2024 to RMB 0.16 [1] Operational Challenges - The decline in revenue was attributed to a slight decrease in outpatient and inpatient visits primarily focused on basic ophthalmic services [1] - The company implemented internal pricing adjustments starting in the second half of 2024 to cope with increasing market competition and the national volume-based procurement (VBP) policy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） (I) 截至二零二五年六月三十日止六個月的中期業績公告；及 (II) 全球發售所得款項用途的預期時間表更新及所得款項用途的變動 財務及經營摘要 本集團的收益由二零二四年同期的人民幣 734.3 百萬元減少 4.9% 至截至二零 二五年六月三十日止六個月的人民幣 698.3 百 萬 元。 本集團的毛利由二零二四年同期的人民幣 336.0 百萬元減少 11.4% 至截至二 零二五年六月三十日止六個月的人民幣 297.7 百 萬 元。毛 利 率 由 二 零 二 四 年 同期的 45.8% 下降至截至二零二五年六月三十日止六個月的 42.6%。 本 ...

Core Viewpoint - The company, Chaoyu Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million, funded by the group's surplus cash rather than proceeds from a global offering [1] Group 1 - The subscription amount for the financial product is RMB 30 million [1] - The funding for this subscription comes from the company's surplus cash [1] - The subscription is scheduled for August 22, 2025 [1]

Group 1 - The company, Chaoyu Eye Care (02219), announced that on August 22, 2025, its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million [1] - The subscription will be funded by the group's surplus cash rather than proceeds from a global offering [1]

Group 1 - The core point of the article is that Chaogu Medical Technology, a wholly-owned subsidiary of Chaogu Eye Care, has further subscribed to a financial product from the Bank of China with a total principal amount of RMB 30 million, effective August 22, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 認購理財產品 茲提述本公司日期為二零二四年九月二十七日及二零二五年六月二十四日 的 公 告，內 容 分 別 有 關 認 購 本 金 總 額 為 人 民 幣 240 百 萬 元（「九月存款產品」） 及人民幣 100 百 萬 元（「六月存款產品」）的 中 國 銀 行 結 構 性 存 款 產 品。 董 事 會 宣 佈，於 二 零 二 五 年 八 月 二 十 二 日，朝 聚 醫 療 科 技（本 公 司 的 間 接 全 資 附 屬 公 司）進 一 步 認 購 本 金 總 額 為 人 民 幣 30 百 萬 元 的 中 國 銀 行 理 財 產 品。 認 ...

格隆汇8月14日丨朝聚眼科(02219.HK)公布，董事会会议将于2025年8月29日(星期五)举行，藉以(其中包 括)考虑及批准集团截至2025年6月30日止六个月的中期业绩及其发布，并考虑派发中期股息(如有)。 ...